BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NKTR-102: Updated Phase II data

Updated data from an open-label Phase II trial in 66 evaluable patients who failed a prior taxane-based therapy showed that 145 mg/m 2 NKTR-102 as a single agent led to an ORR of 29%, with 32% and 26% response...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >